Kindeva, a contract development and manufacturing organisation (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organisation as global chief commercial officer (CCO).

Stevens will spearhead the commercial, business development, and research and development activities for the business to ensure continued growth, expansion, and innovation.

Kindeva CEO Milton Boyer said: “David brings a breadth of industry experience and a depth of commercial expertise that is essential for driving Kindeva’s enhanced scope and scale. His role is vital to our continued success as a premier CDMO and, in turn, the success of our partners bringing a broad range of drug delivery solutions to market.”

Stevens has more than 20 years of international operations and commercial experience across both the CDMO and contract research organisation (CRO) sectors. Prior to Kindeva, Stevens was CEO of advanced therapy CDMO Arranta Bio (acquired by Recipharm in 2022), where he built out two advanced biologics development and GMP manufacturing facilities. He held multiple roles at AMRI prior — leading the company’s drug product business unit through significant growth and capacity expansion. Throughout his tenure, he also held positions at Aptuit, Inveresk, and Charles River Laboratories. Stevens has an MBA in strategy, finance, and marketing from the University of Edinburgh.

Stevens said: “The Kindeva organisation has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges. I am excited to work with the incredible experts bringing many life-changing therapies and the highest-quality products to patients, and I am looking forward to leveraging my commercial, operational, and strategic background to enable continued success for our partners worldwide.”